Literature DB >> 18845534

Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation.

Elizabeth C Finger1, Nam Y Lee, Hye-jin You, Gerard C Blobe.   

Abstract

Transforming growth factor-beta (TGF-beta) signals through three highly conserved cell surface receptors, the type III TGF-beta receptor (T beta RIII), the type II TGF-beta receptor (T beta RII), and the type I TGF-beta receptor (T beta RI) to regulate diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis. Although T beta RI and T beta RII undergo ligand-independent endocytosis by both clathrin-mediated endocytosis, resulting in enhanced signaling, and clathrin-independent endocytosis, resulting in receptor degradation, the mechanism and function of T beta RIII endocytosis is poorly understood. T beta RIII is a heparan sulfate proteoglycan with a short cytoplasmic tail that functions as a TGF-beta superfamily co-receptor, contributing to TGF-beta signaling through mechanisms yet to be fully defined. We have reported previously that T beta RIII endocytosis, mediated by a novel interaction with beta arrestin-2, results in decreased TGF-beta signaling. Here we demonstrate that T beta RIII undergoes endocytosis in a ligand and glycosaminoglycan modification-independent and cytoplasmic domain-dependent manner, with the interaction of Thr-841 in the cytoplasmic domain of T beta RIII with beta-arrestin2 enhancing T beta RIII endocytosis. T beta RIII undergoes both clathrin-mediated and clathrin-independent endocytosis. Importantly, inhibition of the clathrin-independent, lipid raft pathway, but not of the clathrin-dependent pathway, results in decreased TGF-beta1 induced Smad2 and p38 phosphorylation, supporting a specific role for clathrin-independent endocytosis of T beta RIII in regulating both Smad-dependent and Smad-independent TGF-beta signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845534      PMCID: PMC2596377          DOI: 10.1074/jbc.M804741200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Mechanisms of transforming growth factor-beta receptor endocytosis and intracellular sorting differ between fibroblasts and epithelial cells.

Authors:  J J Doré; D Yao; M Edens; N Garamszegi; E L Sholl; E B Leof
Journal:  Mol Biol Cell       Date:  2001-03       Impact factor: 4.138

2.  Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription.

Authors:  M E Engel; M A McDonnell; B K Law; H L Moses
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

3.  Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A.

Authors:  J Esparza-Lopez; J L Montiel; M M Vilchis-Landeros; T Okadome; K Miyazono; F López-Casillas
Journal:  J Biol Chem       Date:  2001-02-05       Impact factor: 5.157

4.  Expression cloning and characterization of the TGF-beta type III receptor.

Authors:  X F Wang; H Y Lin; E Ng-Eaton; J Downward; H F Lodish; R A Weinberg
Journal:  Cell       Date:  1991-11-15       Impact factor: 41.582

5.  Caveolin, a protein component of caveolae membrane coats.

Authors:  K G Rothberg; J E Heuser; W C Donzell; Y S Ying; J R Glenney; R G Anderson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

6.  Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor.

Authors:  B Razani; X L Zhang; M Bitzer; G von Gersdorff; E P Böttinger; M P Lisanti
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

7.  Beta-arrestin- and dynamin-dependent endocytosis of the AT1 angiotensin receptor.

Authors:  Z Gáborik; M Szaszák; L Szidonya; B Balla; S Paku; K J Catt; A J Clark; L Hunyady
Journal:  Mol Pharmacol       Date:  2001-02       Impact factor: 4.436

8.  Binding of two growth factor families to separate domains of the proteoglycan betaglycan.

Authors:  J L Andres; D DeFalcis; M Noda; J Massagué
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

9.  Transforming growth factor-beta (TGF-beta) receptor proteoglycan. Cell surface expression and ligand binding in the absence of glycosaminoglycan chains.

Authors:  S Cheifetz; J Massagué
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

10.  A single internalization signal from the di-leucine family is critical for constitutive endocytosis of the type II TGF-beta receptor.

Authors:  M Ehrlich; A Shmuely; Y I Henis
Journal:  J Cell Sci       Date:  2001-05       Impact factor: 5.285

View more
  35 in total

1.  Coated pit-mediated endocytosis of the type I transforming growth factor-β (TGF-β) receptor depends on a di-leucine family signal and is not required for signaling.

Authors:  Keren E Shapira; Avner Gross; Marcelo Ehrlich; Yoav I Henis
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

Review 2.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 3.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

Review 4.  The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Authors:  Yuri K Peterson; Louis M Luttrell
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

5.  Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC.

Authors:  Todd A Townsend; Jamille Y Robinson; Tam How; Daniel M DeLaughter; Gerard C Blobe; Joey V Barnett
Journal:  Cell Signal       Date:  2011-09-14       Impact factor: 4.315

Review 6.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

7.  Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.

Authors:  Erik H Knelson; Angela L Gaviglio; Alok K Tewari; Michael B Armstrong; Karthikeyan Mythreye; Gerard C Blobe
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

8.  The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Authors:  Jason D Lee; Nadine Hempel; Nam Y Lee; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

9.  Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones.

Authors:  Jie Hu; Zhonghua Zhang; Wen-Jun Shen; Salman Azhar
Journal:  Nutr Metab (Lond)       Date:  2010-06-01       Impact factor: 4.169

Review 10.  Involvement of β-arrestins in cancer progression.

Authors:  Shanshan Hu; Di Wang; Jingjing Wu; Juan Jin; Wei Wei; Wuyi Sun
Journal:  Mol Biol Rep       Date:  2012-10-18       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.